|
rs1037733674
|
GCG;LOC101929532
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.040 |
GeneticVariation |
BEFREE |
Our results show that the Gly40Ser mutation in the glucagon receptor gene is not associated with type 2 diabetes in a Brazilian population.
|
11961492 |
2002 |
|
rs1037733674
|
GCG;LOC101929532
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.040 |
GeneticVariation |
BEFREE |
Our results demonstrate a strong genetic heterogeneity among the ethnic group and suggest that the Gly40Ser mutation of the glucagon receptor gene plays little role, if any, in the pathogenesis of type 2 diabetes and essential hypertension in the Taiwanese population.
|
10090412 |
1999 |
|
rs1037733674
|
GCG;LOC101929532
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.040 |
GeneticVariation |
BEFREE |
In conclusion, our results indicate that the Gly40Ser variation is not associated with NIDDM in the Sardinian population and that its frequency varies in different parts of Sardinia.
|
9028723 |
1997 |
|
rs1037733674
|
GCG;LOC101929532
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.040 |
GeneticVariation |
BEFREE |
We have previously reported that a single heterozygous missense mutation in exon 2 of the glucagon receptor gene, which changes a glycine to a serine (Gly40Ser), is associated with NIDDM in a French population.
|
8635644 |
1996 |
|
rs1037733674
|
GCG;LOC101929532
|
Essential Hypertension
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results demonstrate a strong genetic heterogeneity among the ethnic group and suggest that the Gly40Ser mutation of the glucagon receptor gene plays little role, if any, in the pathogenesis of type 2 diabetes and essential hypertension in the Taiwanese population.
|
10090412 |
1999 |
|
rs1037733674
|
GCG;LOC101929532
|
Essential Hypertension
|
|
0.020 |
GeneticVariation |
BEFREE |
1.Previous glucagon receptor gene (GCGR) studies have shown a Gly40Ser mutation to be more prevalent in essential hypertension and to affect glucagon binding affinity to its receptor.
|
9673441 |
1998 |
|
rs980303898
|
GCG;LOC101929532
|
Malignant neoplasm of pancreas
|
|
0.010 |
GeneticVariation |
BEFREE |
K-ras<sup>LSL-G12D/+</sup>:: p53<sup>LSL-R172H/+</sup>:: Pdx-1-Cre (KPC) mice are an established model of pancreatic cancer that specifically express mutants of both K-ras and p53 in the pancreas by using Pdx-1-Cre.
|
28971839 |
2018 |
|
rs980303898
|
GCG;LOC101929532
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
K-ras<sup>LSL-G12D/+</sup>:: p53<sup>LSL-R172H/+</sup>:: Pdx-1-Cre (KPC) mice are an established model of pancreatic cancer that specifically express mutants of both K-ras and p53 in the pancreas by using Pdx-1-Cre.
|
28971839 |
2018 |
|
rs749317102
|
GCG;LOC101929532
|
insulinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
The clinical study was combined with in vitro studies of the synthesis and secretion of p.R46Q-insulin in rat INS-1 insulinoma cells.
|
28478482 |
2017 |
|
rs183433761
|
GCG;LOC101929532
|
Carcinoma of Male Breast
|
|
0.010 |
GeneticVariation |
BEFREE |
Near the sites binding to TATA-binding protein (TBP) in human gene promoters, we found 22 obesity-related candidate SNP markers, including rs10895068 (male breast cancer in obesity); rs35036378 (reduced risk of obesity after ovariectomy); rs201739205 (reduced risk of obesity-related cancers due to weight loss by diet/exercise in obese postmenopausal women); rs183433761 (obesity resistance during a high-fat diet); rs367732974 and rs549591993 (both: cardiovascular complications in obese patients with type 2 diabetes mellitus); rs200487063 and rs34104384 (both: obesity-caused hypertension); rs35518301, rs72661131, and rs562962093 (all: obesity); and rs397509430, rs33980857, rs34598529, rs33931746, rs33981098, rs34500389, rs63750953, rs281864525, rs35518301, and rs34166473 (all: chronic inflammation in comorbidities of obesity).
|
26694100 |
2015 |
|
rs183433761
|
GCG;LOC101929532
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.010 |
GeneticVariation |
BEFREE |
Near the sites binding to TATA-binding protein (TBP) in human gene promoters, we found 22 obesity-related candidate SNP markers, including rs10895068 (male breast cancer in obesity); rs35036378 (reduced risk of obesity after ovariectomy); rs201739205 (reduced risk of obesity-related cancers due to weight loss by diet/exercise in obese postmenopausal women); rs183433761 (obesity resistance during a high-fat diet); rs367732974 and rs549591993 (both: cardiovascular complications in obese patients with type 2 diabetes mellitus); rs200487063 and rs34104384 (both: obesity-caused hypertension); rs35518301, rs72661131, and rs562962093 (all: obesity); and rs397509430, rs33980857, rs34598529, rs33931746, rs33981098, rs34500389, rs63750953, rs281864525, rs35518301, and rs34166473 (all: chronic inflammation in comorbidities of obesity).
|
26694100 |
2015 |
|
rs183433761
|
GCG;LOC101929532
|
Malignant neoplasm of male breast
|
|
0.010 |
GeneticVariation |
BEFREE |
Near the sites binding to TATA-binding protein (TBP) in human gene promoters, we found 22 obesity-related candidate SNP markers, including rs10895068 (male breast cancer in obesity); rs35036378 (reduced risk of obesity after ovariectomy); rs201739205 (reduced risk of obesity-related cancers due to weight loss by diet/exercise in obese postmenopausal women); rs183433761 (obesity resistance during a high-fat diet); rs367732974 and rs549591993 (both: cardiovascular complications in obese patients with type 2 diabetes mellitus); rs200487063 and rs34104384 (both: obesity-caused hypertension); rs35518301, rs72661131, and rs562962093 (all: obesity); and rs397509430, rs33980857, rs34598529, rs33931746, rs33981098, rs34500389, rs63750953, rs281864525, rs35518301, and rs34166473 (all: chronic inflammation in comorbidities of obesity).
|
26694100 |
2015 |
|
rs183433761
|
GCG;LOC101929532
|
Hypertensive disease
|
|
0.010 |
GeneticVariation |
BEFREE |
Near the sites binding to TATA-binding protein (TBP) in human gene promoters, we found 22 obesity-related candidate SNP markers, including rs10895068 (male breast cancer in obesity); rs35036378 (reduced risk of obesity after ovariectomy); rs201739205 (reduced risk of obesity-related cancers due to weight loss by diet/exercise in obese postmenopausal women); rs183433761 (obesity resistance during a high-fat diet); rs367732974 and rs549591993 (both: cardiovascular complications in obese patients with type 2 diabetes mellitus); rs200487063 and rs34104384 (both: obesity-caused hypertension); rs35518301, rs72661131, and rs562962093 (all: obesity); and rs397509430, rs33980857, rs34598529, rs33931746, rs33981098, rs34500389, rs63750953, rs281864525, rs35518301, and rs34166473 (all: chronic inflammation in comorbidities of obesity).
|
26694100 |
2015 |
|
rs183433761
|
GCG;LOC101929532
|
Obesity
|
|
0.010 |
GeneticVariation |
BEFREE |
Near the sites binding to TATA-binding protein (TBP) in human gene promoters, we found 22 obesity-related candidate SNP markers, including rs10895068 (male breast cancer in obesity); rs35036378 (reduced risk of obesity after ovariectomy); rs201739205 (reduced risk of obesity-related cancers due to weight loss by diet/exercise in obese postmenopausal women); rs183433761 (obesity resistance during a high-fat diet); rs367732974 and rs549591993 (both: cardiovascular complications in obese patients with type 2 diabetes mellitus); rs200487063 and rs34104384 (both: obesity-caused hypertension); rs35518301, rs72661131, and rs562962093 (all: obesity); and rs397509430, rs33980857, rs34598529, rs33931746, rs33981098, rs34500389, rs63750953, rs281864525, rs35518301, and rs34166473 (all: chronic inflammation in comorbidities of obesity).
|
26694100 |
2015 |
|
rs770254254
|
GCG;LOC101929532
|
Premature Menopause
|
|
0.010 |
GeneticVariation |
BEFREE |
WNT4 (c.99G>A, p.Ser33Ser) was not associated with POF pathology.
|
22951804 |
2012 |
|
rs770254254
|
GCG;LOC101929532
|
Ovarian Failure, Premature
|
|
0.010 |
GeneticVariation |
BEFREE |
WNT4 (c.99G>A, p.Ser33Ser) was not associated with POF pathology.
|
22951804 |
2012 |
|
rs980303898
|
GCG;LOC101929532
|
Pancreatitis, Chronic
|
|
0.010 |
GeneticVariation |
BEFREE |
In the pancreata of Pdx1-Cre; LSL-Kras(G12D) mice, exendin-4 led to acceleration of the disruption of exocrine architecture and chronic pancreatitis with mucinous metaplasia and increased formation of murine PanIN lesions.
|
22266668 |
2012 |
|
rs980303898
|
GCG;LOC101929532
|
Pancreatic intraepithelial neoplasia
|
|
0.010 |
GeneticVariation |
BEFREE |
In the pancreata of Pdx1-Cre; LSL-Kras(G12D) mice, exendin-4 led to acceleration of the disruption of exocrine architecture and chronic pancreatitis with mucinous metaplasia and increased formation of murine PanIN lesions.
|
22266668 |
2012 |
|
rs766216371
|
GCG;LOC101929532
|
DIABETES MELLITUS, PERMANENT NEONATAL
|
|
0.010 |
GeneticVariation |
BEFREE |
Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy.
|
18571549 |
2008 |
|
rs1037733674
|
GCG;LOC101929532
|
Diabetes
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with diabetes and carriers of Gly40Ser showed basal C-peptide levels significantly lower than noncarriers (0.70 ng/mL versus 1.50 ng/mL, p = 0.008).
|
11961492 |
2002 |
|
rs1037733674
|
GCG;LOC101929532
|
Diabetes Mellitus
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with diabetes and carriers of Gly40Ser showed basal C-peptide levels significantly lower than noncarriers (0.70 ng/mL versus 1.50 ng/mL, p = 0.008).
|
11961492 |
2002 |
|
rs1303328174
|
GCG;LOC101929532
|
Diabetes Mellitus, Insulin-Dependent
|
|
0.010 |
GeneticVariation |
BEFREE |
The nucleotide substitutions in exon 4 in the patient with type 1 diabetes and that with fibrocalculous pancreatopathy occurred at codons 103 and 84 while that in exon 5 in the patient with type 1 diabetes occurred at codon 141, changing the codons from CAT to CAC, GTG to GCG, and ACT to AAT and resulting in H103H silent, V84A and T141N missense mutations, respectively.
|
11796176 |
2002 |
|
rs150179526
|
GCG;LOC101929532
|
Diabetes
|
|
0.010 |
GeneticVariation |
BEFREE |
V125I mutation co-segregated in those 2 initial families, but further association studies showed that this mutation was not associated with diabetes or early age at diagnosis of the disease.
|
11773861 |
2002 |
|
rs150179526
|
GCG;LOC101929532
|
Diabetes Mellitus
|
|
0.010 |
GeneticVariation |
BEFREE |
V125I mutation co-segregated in those 2 initial families, but further association studies showed that this mutation was not associated with diabetes or early age at diagnosis of the disease.
|
11773861 |
2002 |
|
rs375960284
|
GCG;LOC101929532
|
Diabetes Mellitus, Insulin-Dependent
|
|
0.010 |
GeneticVariation |
BEFREE |
The nucleotide substitutions in exon 4 in the patient with type 1 diabetes and that with fibrocalculous pancreatopathy occurred at codons 103 and 84 while that in exon 5 in the patient with type 1 diabetes occurred at codon 141, changing the codons from CAT to CAC, GTG to GCG, and ACT to AAT and resulting in H103H silent, V84A and T141N missense mutations, respectively.
|
11796176 |
2002 |